GEM132 antisense oligonucleotide with modified RNA caps to increase metabolic stability: Phase II Update

(Phase I results, B9).

Hybridon Inc.

Read the full 69 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE